The KEYNOTE-811 trial evaluated pembrolizumab added to trastuzumab plus fluoropyrimidine- and platinum-based chemotherapy in previously untreated HER2-positive gastric and GEJ adenocarcinoma. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.